Treatment of Gilles de la Tourette's Syndrome with Haloperidol

Shapiro, Arthur M.; Shapiro, Elaine

doi:10.1192/bjp.114.508.345

Cited by 125 publications

(44 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, significant side effects, including extrapyramidal symptoms (EPS) such as acute dystonic reactions, Parkinsonism, akathisia, and tardive dyskinesia (Shapiro et al 1973), have led to use of the newer atypical neuroleptics. In recent years, the atypical neuroleptics have been used frequently to treat tics in youth with TD; however, reports have emerged demonstrating serious adverse effects, including substantial weight gain, development of abnormal glucose and lipid metabolism, elevated serum prolactin levels, and=or cardiac effects such as prolongation of the QTc interval (Green 2001).…”

Section: Introductionmentioning

confidence: 99%

Aripiprazole in Children and Adolescents with Tourette's Disorder: An Open-Label Safety and Tolerability Study

Lyon

Samar

Jummani

et al. 2009

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette's disorder (TD). Method: Eleven subjects (10 males) with TD (age 9-19 years, mean 13.36, standard deviation [SD] 3.33) who did not respond or were unable to tolerate previous tic medication were treated with aripiprazole in an open-label, flexible-dosing study over 10 weeks. Tic severity was rated using the Yale Global Tic Severity Scale (YGTSS) and the Clinical Global Impressions Scale for tics (CGI-Tics) at baseline and at follow-up. Results: The mean (AESD) daily dose for aripiprazole was 4.5 AE 3.0 mg. Mean (AESD) YGTSS Global Severity scores reduced from 61.82 AE 13.49 at baseline to 33.73 AE 15.18 at end point; mean YGTSS total tic scores reduced from 28.18 AE 7.74 at baseline to 16.73 AE 7.54 at end point. Mean (AESD) CGI-Tic severity scores reduced from 4.45 AE 0.52 (moderate-marked) at baseline to 3.18 AE 0.60 (mild) at end point. On the CGI-Tic improvement scale, 10 (

show abstract

Section: Introductionmentioning

confidence: 99%

Aripiprazole in Children and Adolescents with Tourette's Disorder: An Open-Label Safety and Tolerability Study

Lyon

Samar

Jummani

et al. 2009

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…The re sponse of both motor and vocal tics to typical neurolep tic agents (Seignot 1961;Shapiro et al 1973) and the demonstration of altered levels of homovanillic acid (HV A) in the cerebrospinal fluid (CSF) of some patients (Cohen et al 1979;Singer et al 1982) have suggested a primary role for the dopamine system in TS, perhaps involving increased sensitivity of dopamine receptors or postsynaptic mechanisms to which these receptors are coupled. However, models derived from pharmaco logic information in this fashion inevitably suffer from a lack of anatomic specifIcity.…”

mentioning

confidence: 99%

The Functional Neuroanatomy of Tourette's Syndrome: An FDG-PET Study. I. Regional Changes in Cerebral Glucose Metabolism Differentiating Patients and Controls

Braun

Stoetter

Randolph

et al. 1993

Neuropsychopharmacol

159

View full text Add to dashboard Cite

Regional metabolic rates for glucose estimated using [18Flfluorodeoxyglucose positron-emission tomography were compared in 16 drug-free patients with Tourette's syndrome (TS) and 16 age-and sex-matched normal volunteers. Tourette's syndrome patients were characterized by decreased normalized metabolic rates in paralimbic and ventral prefrontal cortices, particularly in orbitofrontal, inferior insular, and parahippocampal regions. Similar decreases were observed in subcortical regions, including the ventral striatum (nucleus accumbenslventromedial caudate) and in the midbrain. Published by Elsevier Science Publishing Co., Inc.655 Avenue of the Americas, New York, NY 10010These changes were more robust and occurred with greater frequency in the left hemisphere. They were associated with concomitant bilateral increases in metabolic activity the supplementary motor, lateral premotor, and Rolandic cortices. Effects of prior exposure to neuroactive drugs did not account for these findings. These results suggest that an altered relationship between limbic-related regions of the cortex and striatum and cortical regions involved in the initiation of movement may play a role in the pathogenesis of this illness.

show abstract

“…Multiple clinicians (Seignot 1961;Challas and Brauer 1963;Chapel et al 1964;Abuzzahab and Anderson 1973;Shapiro et al 1973) reported the efficacy of haloperidol (HAL) in the treatment of tics and TD (Table 1). HAL was approved by the FDA for the treatment of adult TD patients in 1969 and for children in 1978.…”

Section: Classic or Typical Antipsychoticsmentioning

confidence: 99%

An Overview of the Treatment of Tourette's Disorder and Tics

Párraga

Harris

Párraga

et al. 2010

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: The aim of this study was to review the efficacy of various treatments for Tourette's disorder (TD) and tics. Method: This study is a historical review of the treatment modalities prior to the advent of neuroleptics. A review of doubleblind and placebo-controlled clinical trials and open studies on the use of neuroleptics and selected reports was also carried out. Results: The literature review reveals that the treatment of TD and tics has evolved from an early history of marginally effective approaches to the advent of neuroleptics, which started a new era in TD and tic treatment, with a significantly broader range of effectiveness. Conclusions: Although progress has been made, the literature review nevertheless reveals a great deal of confusion as related to the clinical heterogeneity of TD and tics, differences in populations, medication-dose combinations, and outcomes. However, a role for a limited number of pharmacologic agents, combined with psychosocial approaches, has been identified. There is a need for studies in larger, diagnostically homogenous samples and for the use of more sophisticated methodology, to identify intelligible models that would allow the development of more effective treatment approaches.

show abstract

Treatment of Gilles de la Tourette's Syndrome with Haloperidol

Cited by 125 publications

References 15 publications

Aripiprazole in Children and Adolescents with Tourette's Disorder: An Open-Label Safety and Tolerability Study

Aripiprazole in Children and Adolescents with Tourette's Disorder: An Open-Label Safety and Tolerability Study

The Functional Neuroanatomy of Tourette's Syndrome: An FDG-PET Study. I. Regional Changes in Cerebral Glucose Metabolism Differentiating Patients and Controls

An Overview of the Treatment of Tourette's Disorder and Tics

Contact Info

Product

Resources

About